Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A global perspective on vasoactive agents in shock|
de Backer, D.
|Citation:||Intensive Care Medicine, 2018; 44(6):833-846|
|Djillali Annane, Lamia Ouanes-Besbes, Daniel de Backer, Bin DU, Anthony C. Gordon ... Sandra Peake ... et al.|
|Abstract:||PURPOSE:We set out to summarize the current knowledge on vasoactive drugs and their use in the management of shock to inform physicians' practices. METHODS:This is a narrative review by a multidisciplinary, multinational-from six continents-panel of experts including physicians, a pharmacist, trialists, and scientists. RESULTS AND CONCLUSIONS:Vasoactive drugs are an essential part of shock management. Catecholamines are the most commonly used vasoactive agents in the intensive care unit, and among them norepinephrine is the first-line therapy in most clinical conditions. Inotropes are indicated when myocardial function is depressed and dobutamine remains the first-line therapy. Vasoactive drugs have a narrow therapeutic spectrum and expose the patients to potentially lethal complications. Thus, these agents require precise therapeutic targets, close monitoring with titration to the minimal efficacious dose and should be weaned as promptly as possible. Moreover, the use of vasoactive drugs in shock requires an individualized approach. Vasopressin and possibly angiotensin II may be useful owing to their norepinephrine-sparing effects.|
|Keywords:||Shock; cardiovascular system; adrenergic agonists; clinical trials; practice guidelines|
|Rights:||© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.